Jupitab-F Tablet is a combination lipid-lowering medication containing Fenofibrate 160 mg and Rosuvastatin 10 mg, indicated for the management of dyslipidemia and mixed hyperlipidemia. Fenofibrate, a fibric acid derivative, primarily reduces triglyceride levels and increases high-density lipoprotein cholesterol (HDL-C) by activating peroxisome proliferator-activated receptor alpha (PPARα), enhancing lipolysis and elimination of triglyceride-rich particles. Rosuvastatin, a potent HMG-CoA reductase inhibitor, effectively lowers low-density lipoprotein cholesterol (LDL-C) by inhibiting the rate-limiting step in cholesterol biosynthesis, leading to increased clearance of LDL particles. The synergistic action of these agents provides comprehensive lipid control, reducing cardiovascular risk in patients with mixed dyslipidemia not adequately managed by monotherapy. Jupitab-F is indicated as an adjunct to diet and lifestyle modifications for patients with hypercholesterolemia, hypertriglyceridemia, or combined dyslipidemia. It is essential to monitor liver function tests and creatine kinase levels periodically due to the risk of hepatotoxicity and myopathy. Contraindications include active liver disease, severe renal impairment, and hypersensitivity to either component. Patient adherence to prescribed dosage and regular follow-up are critical to achieving optimal therapeutic outcomes and minimizing adverse effects.